Wedbush Initiates Coverage On Crescent Biopharma with Outperform Rating, Announces Price Target of $27
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.
Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.
Trade with 70% Backtested Accuracy
Analyst Views on CBIO
About CBIO
About the author
Crescent Biopharma to Participate in Biotech Summit 2026
- Management Participation: Crescent Biopharma is scheduled to participate in the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, in New York, showcasing its latest advancements in cancer therapies, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast Availability: The event will be webcast live on the company's website, with a replay accessible for 90 days post-event, enhancing interaction with investors and increasing transparency and trust.
- Pipeline Overview: Crescent Biopharma's clinical-stage pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs), aiming to rapidly advance cancer treatments that could transform existing therapeutic paradigms.
- Company Vision: Crescent Biopharma is committed to becoming a world-leading oncology company, leveraging multiple modalities and combination regimens to rapidly advance potentially transformative therapies for a range of solid tumors, demonstrating its strategic ambition in the biotech sector.
Analysts Bullish on Century Communities, Target Price Set at $92
- Century Communities Rating: Analyst James McCanless initiated coverage on Century Communities Inc (NYSE:CCS) with a Market Outperform rating and a price target of $92, indicating significant upside from Tuesday's close of $66.26, reflecting confidence in the company's growth prospects.
- Alumis Inc Rating: Chardan Capital analyst Janani Sundararajan initiated coverage on Alumis Inc (NASDAQ:ALMS) with a Buy rating and a price target of $37, suggesting a 41% upside from Tuesday's close of $26.06, showcasing optimism about its business outlook.
- Credo Technology Rating: Rosenblatt analyst Mike Genovese initiated coverage on Credo Technology Group Holding Ltd (NASDAQ:CRDO) with a Neutral rating and a price target of $170, indicating potential upside from the current price of $153.22, reflecting a cautious view on its market performance.
- Crescent Biopharma Rating: Guggenheim analyst Brad Canino initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and a price target of $35, representing a 150% upside from Tuesday's close of $13.98, indicating strong confidence in its future growth potential.
Crescent Biopharma Grants 129,626 Stock Options to Attract Talent
- Options Grant: Crescent Biopharma's Board approved the grant of 129,626 stock options to three non-executive employees as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting key talent and enhancing team stability.
- Incentive Structure: The options have an exercise price of $13.21 per share, aligning with the closing price on December 15, 2025, ensuring that employees can benefit financially as the company performs well.
- Vesting Schedule: Options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring long-term employee commitment through continuous service with Crescent.
- Strategic Aim: By implementing such incentive measures, Crescent Biopharma aims to build an efficient oncology team to rapidly advance innovative therapies like its PD-1 x VEGF bispecific antibody, further solidifying its market position in the biotechnology sector.
Crescent Biopharma Unveils Inducement Award Grants
Equity Inducement Awards: Crescent Biopharma's Board approved the grant of options to purchase 129,626 shares to three non-executive employees as part of their 2025 Employment Inducement Incentive Award Plan, with options granted on December 15, 2025.
Option Details: The options have a 10-year term with an exercise price of $13.21 per share, vesting over time based on the employees' continuous service with the company.
Company Vision: Crescent Biopharma aims to become a leading oncology company, focusing on developing innovative therapies for cancer patients, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates.
Pipeline Strategy: The company plans to advance transformative therapies for solid tumors through various modalities and combination regimens, enhancing treatment options for patients.
What’s Going On With Crescent Biopharma Stock Today?
Partnership Announcement: Crescent Biopharma has formed an exclusive partnership with Sichuan Kelun-Biotech to develop next-generation oncology therapeutics, including the bispecific antibody CR-001 and various antibody-drug conjugates.
Private Placement Details: The company secured a $185 million private placement to support clinical development, with expected closure around December 8, 2023, and participation from several investment firms.
Pipeline Timeline: Crescent anticipates that its products CR-001, CR-002, and CR-003 will enter clinical trials in 2026, with initial proof-of-concept data expected in 2027.
Market Reaction: Following the announcement, Crescent Biopharma's shares experienced a decline of 2.31%, trading at $13.10 at the time of reporting.
Crescent and Kelun-Biotech Finalize Oncology Partnership; Crescent Plans to Raise $185 Million; Stock Price Increases
Partnership Announcement: Crescent Biopharma, Inc. has formed an exclusive partnership with Sichuan Kelun-Biotech to develop and commercialize oncology therapeutics, including CR-001 and SKB105, with both expected to enter Phase 1/2 trials in 2026.
Financial Details: The collaboration includes significant financial arrangements, with Kelun-Biotech receiving an $80 million upfront payment and potential milestone payments totaling up to $1.25 billion, while Crescent will receive $20 million upfront and up to $30 million in milestones.
Private Securities Deal: Crescent Biopharma has also announced a private securities deal expected to raise approximately $185 million, which will fund key clinical data readouts starting in 2027 and extend the company's cash runway into 2028.
Market Reaction: Following the announcement, Crescent Biopharma's shares surged over 36% in pre-market trading, reflecting positive investor sentiment regarding the partnership and funding initiatives.
Crescent Biopharma to Participate in Biotech Summit 2026
- Management Participation: Crescent Biopharma is scheduled to participate in the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, in New York, showcasing its latest advancements in cancer therapies, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast Availability: The event will be webcast live on the company's website, with a replay accessible for 90 days post-event, enhancing interaction with investors and increasing transparency and trust.
- Pipeline Overview: Crescent Biopharma's clinical-stage pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs), aiming to rapidly advance cancer treatments that could transform existing therapeutic paradigms.
- Company Vision: Crescent Biopharma is committed to becoming a world-leading oncology company, leveraging multiple modalities and combination regimens to rapidly advance potentially transformative therapies for a range of solid tumors, demonstrating its strategic ambition in the biotech sector.
Analysts Bullish on Century Communities, Target Price Set at $92
- Century Communities Rating: Analyst James McCanless initiated coverage on Century Communities Inc (NYSE:CCS) with a Market Outperform rating and a price target of $92, indicating significant upside from Tuesday's close of $66.26, reflecting confidence in the company's growth prospects.
- Alumis Inc Rating: Chardan Capital analyst Janani Sundararajan initiated coverage on Alumis Inc (NASDAQ:ALMS) with a Buy rating and a price target of $37, suggesting a 41% upside from Tuesday's close of $26.06, showcasing optimism about its business outlook.
- Credo Technology Rating: Rosenblatt analyst Mike Genovese initiated coverage on Credo Technology Group Holding Ltd (NASDAQ:CRDO) with a Neutral rating and a price target of $170, indicating potential upside from the current price of $153.22, reflecting a cautious view on its market performance.
- Crescent Biopharma Rating: Guggenheim analyst Brad Canino initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and a price target of $35, representing a 150% upside from Tuesday's close of $13.98, indicating strong confidence in its future growth potential.
Crescent Biopharma Grants 129,626 Stock Options to Attract Talent
- Options Grant: Crescent Biopharma's Board approved the grant of 129,626 stock options to three non-executive employees as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting key talent and enhancing team stability.
- Incentive Structure: The options have an exercise price of $13.21 per share, aligning with the closing price on December 15, 2025, ensuring that employees can benefit financially as the company performs well.
- Vesting Schedule: Options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring long-term employee commitment through continuous service with Crescent.
- Strategic Aim: By implementing such incentive measures, Crescent Biopharma aims to build an efficient oncology team to rapidly advance innovative therapies like its PD-1 x VEGF bispecific antibody, further solidifying its market position in the biotechnology sector.
Crescent Biopharma Unveils Inducement Award Grants
Equity Inducement Awards: Crescent Biopharma's Board approved the grant of options to purchase 129,626 shares to three non-executive employees as part of their 2025 Employment Inducement Incentive Award Plan, with options granted on December 15, 2025.
Option Details: The options have a 10-year term with an exercise price of $13.21 per share, vesting over time based on the employees' continuous service with the company.
Company Vision: Crescent Biopharma aims to become a leading oncology company, focusing on developing innovative therapies for cancer patients, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates.
Pipeline Strategy: The company plans to advance transformative therapies for solid tumors through various modalities and combination regimens, enhancing treatment options for patients.
What’s Going On With Crescent Biopharma Stock Today?
Partnership Announcement: Crescent Biopharma has formed an exclusive partnership with Sichuan Kelun-Biotech to develop next-generation oncology therapeutics, including the bispecific antibody CR-001 and various antibody-drug conjugates.
Private Placement Details: The company secured a $185 million private placement to support clinical development, with expected closure around December 8, 2023, and participation from several investment firms.
Pipeline Timeline: Crescent anticipates that its products CR-001, CR-002, and CR-003 will enter clinical trials in 2026, with initial proof-of-concept data expected in 2027.
Market Reaction: Following the announcement, Crescent Biopharma's shares experienced a decline of 2.31%, trading at $13.10 at the time of reporting.
Crescent and Kelun-Biotech Finalize Oncology Partnership; Crescent Plans to Raise $185 Million; Stock Price Increases
Partnership Announcement: Crescent Biopharma, Inc. has formed an exclusive partnership with Sichuan Kelun-Biotech to develop and commercialize oncology therapeutics, including CR-001 and SKB105, with both expected to enter Phase 1/2 trials in 2026.
Financial Details: The collaboration includes significant financial arrangements, with Kelun-Biotech receiving an $80 million upfront payment and potential milestone payments totaling up to $1.25 billion, while Crescent will receive $20 million upfront and up to $30 million in milestones.
Private Securities Deal: Crescent Biopharma has also announced a private securities deal expected to raise approximately $185 million, which will fund key clinical data readouts starting in 2027 and extend the company's cash runway into 2028.
Market Reaction: Following the announcement, Crescent Biopharma's shares surged over 36% in pre-market trading, reflecting positive investor sentiment regarding the partnership and funding initiatives.
